<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; NSSO</title>
	<atom:link href="http://www.tapanray.in/tag/nsso/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Awaiting The Two To Tango: Pharma Innovation And Public Health Interest</title>
		<link>http://www.tapanray.in/awaiting-the-two-to-tango-pharma-innovation-and-public-health-interest/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=awaiting-the-two-to-tango-pharma-innovation-and-public-health-interest</link>
		<comments>http://www.tapanray.in/awaiting-the-two-to-tango-pharma-innovation-and-public-health-interest/#comments</comments>
		<pubDate>Mon, 02 Jan 2017 00:00:28 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Africa]]></category>
		<category><![CDATA[awaiting]]></category>
		<category><![CDATA[countries]]></category>
		<category><![CDATA[developed]]></category>
		<category><![CDATA[Developing]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[expectancy]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[IGWG]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[life]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[NSSO]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[OSDD]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[pricey]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[source]]></category>
		<category><![CDATA[tango]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[tropical]]></category>
		<category><![CDATA[two]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8029</guid>
		<description><![CDATA[“The rewards for the breakthrough drug discovery must be substantial, but if prices are the only mechanism through which returns on research flow, affordability will be compromised,” articulated an article titled, ‘Pharmaceutical Policy Reform &#8211; Balancing Affordability with Incentives for Innovation’, &#8230; <a href="http://www.tapanray.in/awaiting-the-two-to-tango-pharma-innovation-and-public-health-interest/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/awaiting-the-two-to-tango-pharma-innovation-and-public-health-interest/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Union Budget 2014-15: Ticks The ‘Top Priority’ Boxes on Healthcare</title>
		<link>http://www.tapanray.in/union-budget-2014-15-ticks-the-top-priority-boxes-on-healthcare/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=union-budget-2014-15-ticks-the-top-priority-boxes-on-healthcare</link>
		<comments>http://www.tapanray.in/union-budget-2014-15-ticks-the-top-priority-boxes-on-healthcare/#comments</comments>
		<pubDate>Mon, 14 Jul 2014 00:00:17 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2014-15]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[AIIMS]]></category>
		<category><![CDATA[All]]></category>
		<category><![CDATA[biotechnology]]></category>
		<category><![CDATA[Budget]]></category>
		<category><![CDATA[building]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Capacity]]></category>
		<category><![CDATA[diagnostics]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[ease]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[Free]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[insurance]]></category>
		<category><![CDATA[MHRC]]></category>
		<category><![CDATA[NIA]]></category>
		<category><![CDATA[NSSO]]></category>
		<category><![CDATA[oop]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[pre-budget]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Union]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5594</guid>
		<description><![CDATA[The Union Budget 2014-15, especially for healthcare, needs to be analyzed against the backdrop of what the common patients have been going through in the healthcare space of India, over a period of time. In that context, I would quote &#8230; <a href="http://www.tapanray.in/union-budget-2014-15-ticks-the-top-priority-boxes-on-healthcare/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/union-budget-2014-15-ticks-the-top-priority-boxes-on-healthcare/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
